Clinical Trials Logo

Clinical Trial Summary

Double-blinded, randomised controlled trial to evaluate the clinical efficacy of a single dose of oral capsule-administered faecal microbiota transplantation (FMT) for carbapenemase-producing Enterobacteriaceae (CPE) intestinal decolonisation compared with placebo. Primary outcome is the proportion of patients successfully decolonised of CPE intestinal carriage at 12 weeks after FMT treatment compared with placebo.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04746222
Study type Interventional
Source Tan Tock Seng Hospital
Contact Oon Tek Ng, MBBS
Phone +65 6357 7318
Email Oon_Tek_NG@ttsh.com.sg
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date July 2021
Completion date July 2023

See also
  Status Clinical Trial Phase
Recruiting NCT06051513 - Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection N/A
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Completed NCT04146337 - Fecal Microbiota Transplantation for Carbapenem-resistant Enterobacteriaceae Phase 2/Phase 3
Completed NCT04167228 - Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria
Terminated NCT04876430 - Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems Phase 2/Phase 3
Enrolling by invitation NCT03924934 - Community-associated Highly-Resistant Enterobacterales
Recruiting NCT04583098 - The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms
Recruiting NCT04535661 - Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children
Withdrawn NCT04785924 - Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections Phase 4
Terminated NCT05258851 - Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections Phase 3
Recruiting NCT04014413 - Safety and Efficacy of Fecal Microbiota Transplantation N/A
Recruiting NCT05871476 - Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals N/A
Recruiting NCT05850871 - Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies N/A
Terminated NCT05210387 - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections N/A
Not yet recruiting NCT06210542 - Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model
Not yet recruiting NCT05981430 - Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae N/A
Recruiting NCT06258551 - Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
Recruiting NCT05979545 - EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics Phase 4
Completed NCT04790565 - Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae Phase 2/Phase 3